Overview
Medical device maker's Q4 2025 sales rose 5%, beating analyst expectations
Adjusted EPS for Q4 2025 beat analyst expectations
Company repurchased 698,356 shares for $50 mln, plans accelerated share repurchase
Outlook
Integer maintains 2026 sales growth midpoint from October outlook
Integer anticipates 2026 adjusted EPS growth at high end of October outlook
Company expects 200bps above-market organic sales growth in 2027
Result Drivers
CARDIO & VASCULAR GROWTH - Sales increased 11% in Q4 2025, driven by acquisitions and strong demand in Neurovascular
NEUROMODULATION DECLINE - Cardiac Rhythm Management & Neuromodulation sales decreased 2% in Q4 2025, due to lower demand from select emerging customers
OTHER MARKETS DECLINE - Sales decreased 13% in Q4 2025, impacted by the exit from Portable Medical
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Sales | Beat | $472 mln | $462.73 mln (9 Analysts) |
Q4 Adjusted EPS | Beat | $1.76 | $1.70 (8 Analysts) |
Q4 EPS | $1.38 | ||
Q4 Adjusted Net Income | Slight Beat* | $62 mln | $61.81 mln (7 Analysts) |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Integer Holdings Corp is $87.00, about 0.6% above its February 18 closing price of $86.48
The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 10 three months ago
Press Release: ID:nGNXbfKTzX
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)